- 著者
- Ban Hiroshi Yamamoto Hiroki Hanakawa Takashi Urayama Shin-Ichi Aso Toshihiko Fukuyama Hidenao Ejima Yoshimichi
- 出版者
- The Society for Neuroscience
- 雑誌
- The Journal of neuroscience : the official journal of the Society for Neuroscience (ISSN:02706474)
- 巻号頁・発行日
- vol.33, no.43, pp.16992-17007, 2013-10-23
- 被引用文献数
- 35
モノの背後を見る脳の仕組みを解明 -視対象の部分像から全体像を復元する第1次視覚野の活動をfMRIで観察-. 京都大学プレスリリース. 2013-10-23.
- 著者
- Ong Siew Mei Yamamoto Hiroki Saeki Kohei Tanaka Yuiko Yoshitake Ryohei Nishimura Ryohei Nakagawa Takayuki
- 出版者
- Graduate School of Veterinary Medicine, Hokkaido University
- 雑誌
- Japanese Journal of Veterinary Research (ISSN:00471917)
- 巻号頁・発行日
- vol.65, no.1, pp.17-28, 2017-02
Numerous topoisomerase inhibitors with proven efficacy have been used extensively to treat various human neoplasms. However, among these, only doxorubicin has been used and studied extensively in veterinary oncology. The current study was performed to evaluate the responsiveness of canine osteosarcoma (cOSA), mammary gland tumour (cMGT), and malignant melanoma (cMM) cell lines to several topoisomerase inhibitors. In addition, the correlation between the sensitivity to treatment and multi-drug resistant (MDR) factors was investigated. cOSA cell lines exhibited higher sensitivity than cMGT and cMM cell lines to all the topoisomerase inhibitors tested in vitro; this was associated with the levels of multi-drug resistance protein 1 (MDR1) gene expression in the cOSA cell lines. Treatment of cOSA (HMPOS) and cMGT cell line (CHMp) xenograft mouse models with etoposide markedly delayed tumour progression in HMPOS xenografts, but failed to elicit lasting anti-tumour effects on CHMp xenograft mice. The present findings suggest that MDR1 represents a molecular signature for prediction of treatment efficacy of topoisomerase inhibitors, especially that of etoposide, which may be a clinically useful anti-tumour agent for cOSA; however, further study is necessary to refine the treatment protocol.